Company intelligence / Profile preview
discoveric bio alpha
Pfäffikon, Switzerlanddiscovericbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
discoveric bio alpha is conducting lead optimization and translational modeling for its lead bi- or multi-specific antibody program NIDB-3101 targeting Alzheimer's disease, currently in preclinical development. Mechanistic modeling for human PK/target occupancy and dose selection is underway in preparation for first-in-human studies.
- Therapeutic areas
- Neurology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
InSysBio
Beyond the preview
Go deeper on discoveric bio alpha.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on discoveric bio alpha.